Neoantigens: Promising targets for cancer therapy
Neoantigens are specifically expressed only in tumors and are unlikely to induce tolerance and damage normal tissue cells, making them very attractive targets for tumor immunotherapy. Our goal is to utilize neoantigens to target various cancers, including the development of neoantigen vaccines and related targeted therapies, thereby making significant contributions to tumor immunotherapy.
Neoantigen Platform
Alfa Cytology has five advanced technology platforms to support our neoantigen research and is committed to applying neoantigen platforms to the diagnosis and treatment of cancer. Our platform has the characteristics of automation of analysis process, efficient and fast analysis process, portability of analysis platform, and self-learning of analysis algorithm.
5 Scientific Platforms Facilitate the Research of Neoantigens
Neoantigen Screening Platform Neoantigen Peptide Evaluation Platform Neoantigen Peptide Preparation Platform Drug Screening & Validation Platform Neoantigenic Epitope Prediction PlatformNeoantigen Applications
Based on their advantages of tumor specificity and immunogenetics, neoantigens can serve as emerging targets for cancer immunotherapy, and we provide neoantigen-based treatment strategies.
Tel:
Email: